There are no new drugs approved for the treatment of pneumoconiosis for the time being, but there are some drugs (such as pirfenidone and tiloxime hydrochloride) that have entered clinical studies and can be expected.
1. Pirfenidone, which is essentially an antifibrotic drug, can be conditionally used clinically when pneumoconiosis patients develop significant pulmonary fibrosis, but the effectiveness and safety of the treatment for pneumoconiosis need further research.
2. Tiloxime hydrochloride is a kind of drug that can induce the production of interferon in the body after oral intake, which has been proved to be able to inhibit pulmonary fibrosis and reduce the degree of pulmonary fibrosis in patients with pneumoconiosis.
The above two drugs are not recommended for patients to buy and take on their own, and it is recommended to use them under the guidance of professional doctors to avoid serious adverse consequences.